Extended Data Fig. 5: Top 20 decreased kinases in MIB competition proteomics assays with cabozantinib.
From: Cabozantinib for neurofibromatosis type 1–related plexiform neurofibromas: a phase 2 trial
Stacked bar plot for the top 20 decreased kinases representing the summed log2 fold change in MIB binding for two biological replicates incubated in vitro at varying concentrations of cabozantinib vs DMSO.
